Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trials
about
Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data.Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancerDocetaxel in prostate cancer: a familiar face as the new standard in a hormone-sensitive setting.The STAMPEDE trial: paradigm-changing data through innovative trial design.Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC).The very-high-risk prostate cancer: a contemporary update.The expanding role of chemotherapy in prostate cancer.Androgen deprivation therapy with Leuprolide acetate for treatment of advanced prostate cancer.Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer.
P2860
Q26771537-DA320F8F-6A51-4634-A053-AE99D0DB0C79Q26773634-1FBE3F66-470E-45B4-9762-79D716B95528Q33656791-7F54BCE7-8E7B-4C70-944E-5822258B3260Q36163344-1F1174D8-3876-4592-AAFC-C830D255DAB0Q36707077-2B7AB1D0-40B5-43FF-B729-6F6D3FE3EC4AQ38232184-34141129-0E03-4ED1-BDD4-4FA7C040EAAFQ38952181-D4C667AF-2B19-4618-BAF1-70F76ECEEFC2Q38967484-84C53DC2-157E-47E8-A133-2C958FA66AAAQ39003600-7DB11AC6-36B5-418A-8119-282D4296A6A1Q40608123-F4281455-8D3F-41F1-8AC3-5765BD5C82FFQ42125455-8E8500E3-CDEF-4864-9CD7-A13361C968F6
P2860
Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trials
description
2013 nî lūn-bûn
@nan
2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Adjuvant leuprolide with or wi ...... tant lessons for future trials
@ast
Adjuvant leuprolide with or wi ...... tant lessons for future trials
@en
Adjuvant leuprolide with or wi ...... er after radical prostatectomy
@nl
type
label
Adjuvant leuprolide with or wi ...... tant lessons for future trials
@ast
Adjuvant leuprolide with or wi ...... tant lessons for future trials
@en
Adjuvant leuprolide with or wi ...... er after radical prostatectomy
@nl
prefLabel
Adjuvant leuprolide with or wi ...... tant lessons for future trials
@ast
Adjuvant leuprolide with or wi ...... tant lessons for future trials
@en
Adjuvant leuprolide with or wi ...... er after radical prostatectomy
@nl
P2093
P2860
P356
P1433
P1476
Adjuvant leuprolide with or wi ...... tant lessons for future trials
@en
P2093
Adam S Kibel
Cora N Sternberg
Jonathan I Epstein
Mario A Eisenberger
Michael T Schweizer
Peng Huang
Ronald de Wit
P2860
P304
P356
10.1002/CNCR.28270
P407
P577
2013-08-13T00:00:00Z